Samuel Moed is a recently retired executive from Bristol Myers Squibb (BMS; NYSE: BMY), a global biopharma company focused on innovative therapeutics. In his most recent capacity as Head of Corporate Strategy, Sam led the strategic direction of the company with close linkage to all of its major businesses, functions, and geographies. His recent focus was on the $90 billion acquisition and integration of Celgene by BMS. Additionally, he advanced enterprise digital strategy, capabilities and execution. Previously, Sam oversaw strategy for BMS’s Worldwide Pharmaceuticals Group, encompassing a range of global strategic initiatives, and managed a global portfolio of alliances. He also led a number of businesses including as President of U.S. Pharmaceuticals and as President of Worldwide Consumer Healthcare.Today, Sam serves in board and advisory roles supporting companies in the broad HealthTech sector and is an active board member for various education non-profits.